Clinical Trial Update: Study Evaluating rhIL-11 in Left-Sided Ulcerative Colitis [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating rhIL-11 in left-sided ulcerative colitis was terminated. The sponsor Wyeth is now a wholly owned subsidiary of Pfizer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• rhIL-11 (recombinant human interleukin-11)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Ulcerative Colitis, Inflammatory Bowel Disease | Phase 1 | Status: TERMINATED